Revolutionary Protein Quantification Technology TN-cyclon™ to be Presented at JPPS Annual Conference

Breakthrough in Protein Quantification: TN-cyclon™ Technology

A recent advancement in the field of protein quantification, utilizing TN-cyclon™ technology, has gained significant attention. Developed by BioPhenoMA, a startup founded by researchers from Waseda University, this innovative technique enables the detection of extremely low concentrations of proteins, which has been a considerable challenge in biomedical research. The technology will be presented at the 146th Annual Conference of the Japan Pharmaceutical Society (JPPS), taking place from March 27 to 29, 2026, in Osaka.

Focus on Extracellular Vesicles in Cancer Treatment

The research team from Waseda University, specifically from the Biological Sciences department led by Professor Etsuro Ito, will introduce their findings related to the behavior of extracellular vesicles derived from cancer cells and their protein analysis. The study specifically examines the impact of chemotherapy on these vesicles and how TN-cyclon™ facilitates the high-sensitivity quantification of proteins that were previously difficult to measure accurately.

Extracellular vesicles (EVs) play a crucial role in intercellular communication, especially in the context of cancer progression. Understanding the proteins within these vesicles has the potential to unlock new insights into cancer biology, particularly how treatments may alter their properties. However, traditional methods often fall short in sensitivity, leading to a significant gap in research outcomes.

The introduction of TN-cyclon™ represents a significant shift in this landscape, allowing researchers to utilize standard ELISA antibodies while achieving remarkable sensitivity. This opens up new avenues for research that could lead to improved cancer treatment strategies.

Research Presentation Details

During the session titled Cell Structure and Function VI, the research will be presented on March 29, 2026, from 13:10 to 15:10 in Room 4301. The presentation will cover how chemotherapy-induced changes in extracellular vesicles can adversely affect cancer progression, offering fresh insights derived from high-sensitivity protein analyses. The research team includes Akane Sato, Kaito Oi, Masaru Okita, and Etsuro Ito, demonstrating a strong collaboration among upcoming scientists.

The Role of TN-cyclon™ in Modern Research

TN-cyclon™, the flagship technology from BioPhenoMA, allows for the ultra-sensitive detection of microgram-level proteins in blood and EVs. As a promising platform, it provides a cost-effective solution for researchers without requiring complex equipment. This technology is becoming increasingly integrated into biomedical research, especially within the oncology field, where it holds the promise of providing essential insights that can lead to better treatment options.

BioPhenoMA actively seeks collaboration and research proposals related to TN-cyclon™. Areas of interest range from fundamental research themes, including:

- Measurement of proteins in extracellular vesicles
- Validation of proteomic candidate markers

Researchers interested in joint studies are encouraged to refer to the BioPhenoMA project page for more information.

About BioPhenoMA

Founded on April 18, 2023, BioPhenoMA aims to facilitate breakthroughs in the detection of trace-level proteins. With its headquarters in Shinjuku, Tokyo, the company's mission is to provide an accessible platform for protein detection, contributing to advancements in biomedicine. They aspire to create an innovative environment where researchers can easily detect trace proteins and further their contributions to scientific knowledge.

In conclusion, the forthcoming presentation at the JPPS conference marks a significant milestone in the application of TN-cyclon™ technology, potentially revolutionizing how we approach the study of cancer and the underlying mechanisms that drive treatment responses. This event not only highlights the strength of academic research but also the innovation and drive within Japan’s biotech sector.